10 In a rapamycin-resistant diffuse large B-cell lymphoma model, a gene expression profile was generated.27 This model identified lymphoma subsets that were resistant to mTOR inhibitor therapy and mapped compounds targeting Akt as a way of reversing mTOR inhibitor resistance.27 MK-2206 and a rapalog combination was synergistic in other types of malignancies such as B-precursor acute lymphoblastic leukemia,28 cholangiocarcinoma,29 hepatocellular carcinoma30, 31 and neuroblastoma32in vitro and in vivo, in multiple myeloma,33 gastric cancer34 and thyroid cancer35in vitro. Here, MTOR is linked to lymphoma.